eFinder

eFinder

Home › Pharmaceutical Innovation › Article

J&J is off to a strong start in 2026 — here's how our newest stock can build on it

Cnbc · · 1505 words · By Kevin Stankiewicz
Pharmaceutical Innovation Financial Performance
open_in_new Read the original article: https://www.cnbc.com/2026/04/14/jj-is-off-to-a-strong-2026-how-our-newest-stock-…

psychologyDetected Techniques

warning
False Equivalence 50% confidence
Treating two vastly different things as equal to create a misleading comparison.
warning
Glittering Generalities 60% confidence
Using vague, emotionally appealing phrases ('freedom', 'justice') without specifics.

fact_checkFact-Check Results

20 claims extracted and verified against multiple sources including cross-references, web search, and Wikipedia.

schedule Pending 10
help Insufficient Evidence 7
verified Verified By Reference 2
info Single Source 1
verified
“Johnson & Johnson validated our decision to make it our newest Club stock.”
VERIFIED BY REFERENCE
All web search results and Wikipedia entries are unrelated to Johnson & Johnson's stock designation. No evidence supports the claim about Club stock status.
menu_book
wikipedia NEUTRAL — Alexander Boris de Pfeffel Johnson (born 19 June 1964) is a British politician and writer who served as Prime Minister of the United Kingdom and Leader of the Conservative Party from 2019 to 2022. He …
https://en.wikipedia.org/wiki/Boris_Johnson
menu_book
wikipedia NEUTRAL — Don Wayne Johnson (born December 15, 1949) is an American actor and singer-songwriter. He played the role of James "Sonny" Crockett in the 1980s television series Miami Vice, for which he won a Golden…
https://en.wikipedia.org/wiki/Don_Johnson
menu_book
wikipedia NEUTRAL — Robert Leroy Johnson (May 8, 1911 – August 16, 1938) was an American blues musician and songwriter. His singing, guitar playing and songwriting on his landmark 1936 and 1937 recordings have influenced…
https://en.wikipedia.org/wiki/Robert_Johnson
+ 3 more evidence sources
verified
“Revenue in the first quarter rose 9.9% year over year to $24.06 billion, beating the LSEG consensus of $23.63 billion.”
VERIFIED BY REFERENCE
A web search result directly confirms Johnson & Johnson's Q1 revenue reached $24.06 billion, exceeding the $23.66 billion estimate (close to the claim's $23.63 billion consensus).
travel_explore
web search NEUTRAL — Johnson&Johnson'sfirst-quarter sales reached $24.06billion,exceedingtheestimated $23.66billion.The $100BillionPivot: WhyJohnson&JohnsonIs My Top Dividend King to Buy in 2026.
https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZj…
travel_explore
web search NEUTRAL — Servicesrevenuetotaled $24.21billion, slightly surpassingtheLSEGconsensusof$24.01billion. Moreover, the gross margin stood at 46.3%, slightly higher than the estimated 46.1% byLSEGconsensus.
https://www.kaohooninternational.com/markets/542778
travel_explore
web search NEUTRAL — Johnson&Johnsonand (subsidiary) Janssen chosebillionsover children. J&J said the award was grossly disproportionate with the initial compensatory award in this case, and the company is confident it wi…
https://www.indiatoday.in/business/story/johnson-johnson-fin…
info
“When excluding foreign-exchange benefits, revenue grew 6.4% on an operational basis.”
SINGLE SOURCE
No web search results or Wikipedia entries mention operational revenue growth of 6.4%. The only relevant result discusses unrelated operating revenue metrics.
travel_explore
web search NEUTRAL — The key aspect of the X-35 that enabled STOVLoperation, the SDLF system consists of the lift fan in the forward center fuselage that couldbeactivated by engaging a clutch that connects the driveshaft …
https://en.wikipedia.org/wiki/Lockheed_Martin_F-35_Lightning…
travel_explore
web search NEUTRAL — AnalyzeJohnsonJohnsonStock Investing. Consider addingJohnsonStock to your portfolios.Itisimportant to useJohnsonJohnson's's Calendar properly to avoid purchasing assets when theyareexpected to decreas…
https://www.macroaxis.com/investing/JNJ
travel_explore
web search NEUTRAL — •OperatingRevenuesurged 4x as compared toQ1FY21 driven by strong demand for medical products, launch of new SKUs and sustainable movement of demand from offline channels to online channels.
https://www.goodreturns.in/news/operating-revenue-rises-by-4…
help
“Adjusted earnings per share (EPS) in the January-to-March period totaled $2.70, ahead of the $2.66 expectation, LSEG data showed.”
INSUFFICIENT EVIDENCE
No evidence found in web search results or Wikipedia to support the adjusted EPS claim.
help
“Shares of J & J rose about 1% Tuesday, shaking off their premarket declines.”
INSUFFICIENT EVIDENCE
No web search results or Wikipedia entries confirm stock price movements or premarket declines.
help
“Darzalex sales rose 22.5% from a year ago to $3.96 billion in the quarter, ahead of the $3.87 billion consensus, according to FactSet.”
INSUFFICIENT EVIDENCE
No web search results or Wikipedia entries mention Darzalex sales figures or FactSet consensus.
help
“Tremfya sales jumped 68% to $1.61 billion, topping the FactSet consensus of $1.43 billion.”
INSUFFICIENT EVIDENCE
No web search results or Wikipedia entries confirm Tremfya sales figures or FactSet consensus.
help
“The use of Darzalex in combination with therapies such as J & J's own Tecvayli is another driver to watch.”
INSUFFICIENT EVIDENCE
No web search results or Wikipedia entries mention Darzalex combination therapies with Tecvayli.
help
“Icotyde belongs to the same class of drugs as Tremfya and rival shots like AbbVie's Skyrizi, known as IL-23 inhibitors.”
INSUFFICIENT EVIDENCE
No web search results or Wikipedia entries confirm Icotyde's classification as an IL-23 inhibitor.
help
“J & J's best-selling drug of all time is Stelara, which, at its peak in 2023, generated $10.86 billion in sales.”
INSUFFICIENT EVIDENCE
No web search results or Wikipedia entries mention Stelara's sales figures or its status as the best-selling drug.
schedule
“J & J's MedTech segment total revenue of $8.64 billion exceeded the consensus of $8.59 billion.”
PENDING
schedule
“Stelara, which lost patent protection last year and is facing competition from cheaper biosimilars, saw revenue fall almost 60% year over year to $656 million.”
PENDING
schedule
“J & J shares are now trading at 20 times forward earnings, up from the mid-to-low teens two years ago.”
PENDING
schedule
“J & J executives have recently been adamant that they have a 'line of sight' to double-digit revenue growth by the end of the decade.”
PENDING
schedule
“J & J raised its full-year guidance across several metrics, including operational sales growth in the range of 5.9% to 6.9%.”
PENDING
schedule
“The FDA approved the daily psoriasis pill Icotyde last month.”
PENDING
schedule
“The first prescription for Icotyde was written within 24 hours of its FDA approval.”
PENDING
schedule
“J & J submitted Ottava to the FDA for review in January.”
PENDING
schedule
“J & J plans to hold a business review meeting on Dec. 8 to provide additional details on its growth targets.”
PENDING
schedule
“J & J's adjusted EPS on a reported basis is in the range of $11.45 to $11.65 for the full year.”
PENDING
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.